Evidence map›Paper›PMID 21752268›Full record

ArticleBMC cancer2011

Differences in integrin expression and signaling within human breast cancer cells.

Aliakbar Taherian, Xinlei Li, Yongqing Liu, Thomas A Haas

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMC cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 202 citations in OpenAlex.

  1. Article
  2. Article
  3. Secondary Site Ligand for Integrin αVβ3 Enables Targeted mRNA Delivery.Angewandte Chemie (International ed. in English) · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Preparation and preclinical evaluation ofEJNMMI radiopharmacy and chemistry · 2025
    Article
  8. Article
  9. Article
  10. Protein Gas Vesicles ofACS nano · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The molecular mechanism of CD81 antibody inhibition of metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  17. Article
  18. Review
  19. Identifying STEDable BFMolecules (Basel, Switzerland) · 2023
    Article
  20. Review

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Aliakbar TaherianDepartment of Anatomy and Cell Biology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada 7E3 5E5.
Xinlei Li
Yongqing Liu
Thomas A Haas
University of Saskatchewan · CA

Funding

Canadian Institutes of Health Research 128736Canadian Institutes of Health Research 190355
6 · The paper itself

Abstract

backgroundIntegrins are used as prognostic indicators in breast cancer. Following engagement with extracellular matrix proteins, their signaling influences numerous cellular processes including migration, proliferation, and death. Integrin signaling varies between cell types through differential expression of integrin subunits, and changes within a given cell upon exposure to a cell agonist or through changes in its surroundings. These variations in signaling can profoundly affect the phenotypic, tumorogenecity and metastatic properties of cancer cells. In the present study, we investigated if there were differences in the expression of integrins, integrin structures, and integrin co-receptors within three breast cancer cells and if these differences effected integrin signaling.

methodsExpression of integrins, urokinase receptor and vascular endothelial cell growth factor receptor (VEGFR) in metastatic MDA-MB-435 and MDA-MB-231, non-metastatic MCF7 and non-breast cancer Hek-293 cells was measured by flow cytometry. Cell adhesion was assessed using collagen, fibrinogen, fibronectin and vitronectin coated plates. Changes in kinase levels following PMA stimulation, and cell adhesion-induced activation of kinases were determined by western blot analysis. Distribution of actin stress fibers and focal adhesions was assessed by immunocytochemistry.

resultsAll cells expressed αv integrins, while high β5 and αvβ5 expression was restricted to the cancer cells and high β3 and αvβ3 expression was restricted to MDA-MB-435 cells. The two metastatic cells were the least adhesive, but all cells adhered well to most proteins in the absence of PMA. All proliferating cells expressed activated pSrc, but only proliferating metastatic cells expressed high pMEK levels. PMA treatment resulted in time-dependent changes in activated kinase levels, and only MDA-MB-231 cells constitutively expressed high levels of activated pMEK. MDA-MB-435 cells formed more stress fibers and focal adhesions and only exhibited adhesion-induced activation of pMEK and pFAK. All cells expressed the urokinase receptor, but MCF7 cells had markedly higher VEGFR expression. Adhesion induced differential expression of pFAK, pMEK and pERK.

conclusionsThis study demonstrates that breast cancers vary in their expression of integrins, their capacity to form focal adhesion and to signal through integrins. These differences likely contribute to phenotypic variations between cancer lines and account for some of the heterogeneity of breast cancer.

Indexed as

Signal TransductionAdenocarcinomaAntigens, NeoplasmBreast NeoplasmsCell AdhesionCell Line, TumorFemaleFocal AdhesionsGene Expression Regulation, NeoplasticHEK293 CellsHumansIntegrin alphaVbeta3Integrin beta3IntegrinsNeoplasm ProteinsProtein KinasesAntigens, NeoplasmIntegrin alphaVbeta3integrin alphaVbeta5integrin alphavbeta6Integrin beta3IntegrinsNeoplasm ProteinsProtein KinasesReceptors, Urokinase Plasminogen ActivatorReceptors, Vascular Endothelial Growth FactorReceptors, VitronectinTetradecanoylphorbol Acetate

Identifiers

PMID21752268
PMCPMC3146943
OpenAlexW2138164563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.